Core Viewpoint - Maolai Optical (688502.SH) is advancing its financing and expansion plan, having received approval for the issuance of convertible bonds totaling up to 563 million yuan, aimed at enhancing precision optical production and R&D [1][2]. Financing and Investment - The company plans to raise up to 563 million yuan through the issuance of convertible bonds, with net proceeds allocated to ultra-precision optical production, R&D projects, and working capital [2][4]. - The ultra-precision optical production project has a total investment of 417 million yuan, with up to 417 million yuan sourced from the bond proceeds, accounting for approximately 74% of the total fundraising [2][3]. - The ultra-precision optical technology R&D center project has a total investment of 125 million yuan, with up to 123 million yuan from the bond proceeds, representing about 22% of the total [3]. Financial Performance - For the first three quarters of 2025, Maolai Optical reported revenue of 503 million yuan, a year-on-year increase of 34.05%, and a net profit attributable to shareholders of 45.69 million yuan, up 86.57% [1][7]. - The company’s net profit excluding non-recurring items reached 38.92 million yuan, reflecting a growth of 109.45% [1][7]. - Revenue growth is primarily driven by the semiconductor sector and AR/VR testing fields, with the semiconductor sector accounting for 58.80% of total revenue [7]. R&D and Technological Capabilities - Maolai Optical emphasizes R&D, with investments increasing steadily from 54.40 million yuan in 2022 to 62.32 million yuan in the first three quarters of 2025, maintaining a high investment ratio relative to revenue [6]. - The company has developed five core technologies, including precision optical coating and high-precision optical assembly techniques, enhancing its competitive edge [6]. Strategic Partnerships and Market Position - The company has established long-term strategic partnerships with leading global tech firms and research institutions, including Google’s Waymo and Microsoft, enhancing its market position [7]. - New subsidiaries in Shenzhen and Beijing aim to focus on standard product development and local semiconductor industry support, respectively [4].

Group 1 - Digital Zhengtong's subsidiary Baoding Jindi won a bid for a smart water project in Jinan, with a total contract value of 109 million yuan, of which Baoding Jindi's share is approximately 77 million yuan [1] - Lingzhi Software plans to acquire 100% equity of Kaimiride through a combination of cash and stock issuance, with the final transaction price yet to be determined [1] - Tianjin Port's subsidiary plans to transfer 60% equity of China Railway Storage and Transportation, with an estimated value of 37.54 million yuan for the entire equity [2] Group 2 - New Wufeng reported a 56.97% year-on-year increase in pig sales in October, selling 610,000 pigs [3] - New Peng Co. announced a joint investment of approximately 15 million USD with Jabil to build a battery storage box project in Thailand [4] - Maiwei Bio received approval for a clinical trial of its 9MW3811 injection for pathological scars [6] Group 3 - Jiangsu Sopo completed maintenance and resumed production of its methanol and acetic acid facilities [8] - Luoniushan reported a 24.65% year-on-year increase in pig sales revenue in October, totaling 116 million yuan [9][10] - Zhongbei Communication signed a 1 billion yuan comprehensive computing service framework agreement with Xiamen Hongxin Electronics [11] Group 4 - Huayang New Materials announced the resignation of its general manager, Wu Yuehua [12] - Zhongxin Co. used 50 million yuan of idle funds to purchase structured deposits with expected annual returns between 0.55% and 2.05% [14] - Huajian Group's subsidiary signed a construction engineering design contract worth 96.54 million yuan [16] Group 5 - Jianyou Co. received FDA approval for a new production site for its injectable drug [17] - Beilu Pharmaceutical obtained a drug registration certificate for its iodine mepivacaine injection, which is included in the national medical insurance catalog [19] - *ST Yuancheng's stock will be suspended due to falling below the market cap threshold for delisting [20] Group 6 - Xiantan Co. reported a 9.3% year-on-year increase in chicken product sales revenue in October, totaling 503 million yuan [21] - Huanxu Electronics reported an 8.93% year-on-year decrease in consolidated revenue for October, amounting to 5.598 billion yuan [23] - Yisheng Co. reported a 22.97% year-on-year decrease in white feather chicken seed sales revenue in October [25] Group 7 - Yuandong Bio initiated a Phase I/II clinical trial for its ADC drug YLSH003 targeting advanced solid tumors [25] - Xiaoming Co. reported a 34.89% year-on-year decrease in chicken product sales revenue in October [26] - Nanjiao Food reported a 5.27% year-on-year decrease in consolidated revenue for October, totaling 235 million yuan [28] Group 8 - Chuangye Huikang announced a potential change in control, leading to a temporary stock suspension [30] - Tangrenshen reported a 17.91% year-on-year decrease in pig sales revenue in October, totaling 828 million yuan [32][33] - Wancheng Group plans to distribute a cash dividend of 1.5 yuan per 10 shares to shareholders [34] Group 9 - Kangguan Technology plans to distribute a cash dividend of 3.6 yuan per 10 shares to shareholders [36] - Shoudu Online's executive plans to reduce holdings of up to 19,400 shares [38] - Maolai Optical received approval for the issuance of convertible bonds [40] Group 10 - Jinkai New Energy plans to distribute a cash dividend of 0.1 yuan per share to shareholders [41] - Tianchen Medical raised the upper limit for share repurchase to 70 yuan per share [42] - Tianmu Lake used 38 million yuan of idle funds to purchase structured deposits [43]

Core Points - The stock of Maolai Optical (688502) closed at 357.82 yuan on November 10, 2025, down 0.89% from the previous trading day, with a total market capitalization of 18.893 billion yuan [1] - The company announced that it received approval from the China Securities Regulatory Commission (CSRC) for the issuance of convertible bonds to unspecified investors, valid for 12 months from the date of approval [1] Summary by Category Stock Performance - The stock opened at 360.0 yuan, reached a high of 365.0 yuan, and a low of 351.01 yuan, with a trading volume of 2.54 billion yuan and a turnover rate of 4.23% [1] Corporate Actions - The company will issue convertible bonds in accordance with the approved registration and will adhere to relevant laws and regulations, fulfilling disclosure obligations as required [1]

Core Points - The company, Maolai Optics, has received approval from the China Securities Regulatory Commission for the issuance of convertible bonds to unspecified investors [2] - The approval is valid for 12 months from the date of registration [2] - The issuance must strictly follow the application documents and issuance plan submitted to the Shanghai Stock Exchange [2]

Core Viewpoint - The application for the issuance of convertible bonds by Maolai Optical has changed its review status to effective registration, indicating progress in the company's financing efforts [1] Group 1 - Maolai Optical is issuing convertible bonds to unspecified objects, which may enhance its capital structure and provide funding for future projects [1] - The underwriting institution for this issuance is China International Capital Corporation Limited, suggesting a reputable partner in the capital markets [1]

Group 1 - Great Wall Technology has terminated the planning of control change matters and will resume trading on November 10, 2025 [2] - The actual controllers of Great Wall Technology were in discussions for a share transfer that could lead to a change in control, but they decided to terminate the planning due to a lack of consensus on core issues [2] Group 2 - Eight One Steel and other companies or shareholders are under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws [3] - Eight One Steel received a notice from the CSRC regarding the investigation, stating that their production and operations remain normal and will not be significantly affected [3] Group 3 - ST Chang Pharmaceutical has been investigated by the CSRC for suspected false reporting of financial data, which could lead to mandatory delisting if found guilty of major violations [4] - Intercontinental Oil and Gas is also under investigation, but the investigation pertains to a shareholder and does not affect the company's operations [4] Group 4 - Tianyi New Materials has agreed to undergo pre-restructuring due to creditor applications, which is expected to improve the chances of successful restructuring [6] - The pre-restructuring process will facilitate early communication with creditors and potential investors [6] Group 5 - Suzhou Planning intends to acquire 100% of Dongjin Aviation Technology through a combination of share issuance and cash payment, with a transaction price of 250 million yuan [7] - This acquisition aims to create a competitive integrated solution in air traffic management, addressing industry pain points and aligning with the development of the low-altitude economy [7] Group 6 - Del Shares plans to acquire 100% of Aizhuo Intelligent Technology through share issuance and will raise matching funds from specific investors [8] - The transaction has been reviewed and approved by the Shenzhen Stock Exchange's merger and reorganization review committee [8] Group 7 - Degute has decided to terminate its major asset restructuring transaction due to difficulties in forming a satisfactory plan within the effective time window [9] - The termination requires further negotiations and internal approval processes from the involved parties [9] Group 8 - Aerospace Hanyu's subsidiary has won a bid for a project worth approximately 246.3 million yuan, which is expected to positively impact the company's performance [11] - Huachang Communications has elected a new chairman, which may influence the company's strategic direction [11] Group 9 - Maolai Optical has received approval from the CSRC to issue convertible bonds to unspecified investors [12] - Tianchen Medical has adjusted its share repurchase plan, increasing the maximum repurchase price and total amount [12] Group 10 - Jiangsu Youxian's controlling shareholder plans to increase its stake in the company by investing between 100 million and 150 million yuan [21] - Jian Ke Institute plans to reduce its holdings by up to 1,466,600 shares [21]

Core Points - The company, Maolai Optics, has received approval from the China Securities Regulatory Commission for the issuance of convertible bonds to unspecified investors [1] - The issuance must be conducted strictly according to the submitted documents and issuance plan to the Shanghai Stock Exchange [1] - The approval is valid for 12 months from the date of registration [1] - The company is required to report any significant events to the Shanghai Stock Exchange from the date of registration until the completion of the issuance [1]

三、本批复自同意注册之日起 12 个月内有效。 四、自同意注册之日起至本次发行结束前，公司如发生重大事项，应及时报 告上海证券交易所并按有关规定处理。 公司董事会将根据相关法律法规及上述批复文件的要求，在股东会的授权范 围内办理本次向不特定对象发行可转换公司债券的相关事宜，公司将根据该事项 的进展情况，按照有关规定和要求及时履行信息披露义务。敬请广大投资者注意 投资风险。 证券代码：688502 证券简称：茂莱光学 公告编号：2025-080 南京茂莱光学科技股份有限公司 关于向不特定对象发行可转换公司债券申请获得 中国证券监督管理委员会同意注册批复的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 南京茂莱光学科技股份有限公司（以下简称"公司"）于近日收到中国证券监 督管理委员会出具的《关于同意南京茂莱光学科技股份有限公司向不特定对象发 行可转换公司债券注册的批复》（证监许可〔2025〕2433 号），现将批复文件 主要内容公告如下： 一、同意公司向不特定对象发行可转换公司债券的注册申请。 二、公司本次发行应严格按照 ...

Core Viewpoint - The company, Maolai Optical (688502.SH), has received approval from the China Securities Regulatory Commission (CSRC) for the registration of its convertible bond issuance to unspecified investors [1] Group 1 - The approval is documented in the CSRC's notice numbered 2433, dated 2025 [1] - The company plans to issue convertible bonds, which allows investors to convert their bonds into shares at a later date [1]

Core Viewpoint - The company, Maolai Optical (688502.SH), has received approval from the China Securities Regulatory Commission for the registration of its convertible bond issuance to unspecified investors [1] Group 1 - The company has recently announced the receipt of a formal approval document from the China Securities Regulatory Commission [1] - The approval pertains to the company's application to issue convertible bonds [1] - The registration number for the approval is 证监许可〔2025〕2433号 [1]